Scan.com raises $220M in Series C equity and debt financing
YZR CapitalCompany
Oxford CapitalInvestor
Atempo GrowthInvestor
Scan.com closed a $220 million Series C financing on Aug. 31, 2026, comprising a $90 million equity round led by Noteus Partners and a $130 million debt facility underwritten by VerisFi Capital and Atempo Growth, to fund U.S. expansion of its AI‑driven diagnostic imaging platform and prep for an IPO.
Scan.com announced a $220 million capital raise on Aug. 31, 2026, blending a $90 million Series C equity tranche led by Noteus Partners with a $130 million debt facility underwritten by VerisFi Capital and Atempo Growth. The financing brings total capital raised to roughly $277 million and is earmarked for nationwide rollout of its API‑first diagnostic imaging platform, aggressive M&A of regional scheduling networks, and further development of its agentic AI engine.
Deal Terms
The equity round featured participation from Aviva Ventures, Concord Health Partners, YZR Capital and Oxford Capital, while the debt package is structured as non‑dilutive acquisition financing. Scan.com’s leadership highlighted that the dual‑tranche structure allows rapid balance‑sheet consolidation of independent imaging centres without sacrificing shareholder ownership. The company reported a doubled revenue run‑rate to $165 million, up from $85 million the prior year, and has processed diagnostic pathways for over 900 000 patients.
Strategic Rationale
The U.S. diagnostic imaging market, valued at $100 billion and projected to reach $121 billion by 2033, remains fragmented, with 85 % of outpatient bookings still handled via phone and fax. Scan.com’s asset‑light model aggregates under‑utilised scanner capacity through real‑time scheduling APIs, price‑transparent marketplaces, and a 48‑hour subspecialty reporting pipeline. Its agentic AI evaluates clinical intent, equipment specifications, availability and negotiated fees to match patients with the optimal facility, compressing referral‑to‑scan windows from weeks to under seven days. The new capital will accelerate this model, fund targeted acquisitions of niche scheduling‑software firms, and support a pre‑IPO balance sheet.
The financing also signals confidence from both European growth equity (Noteus) and strategic corporate investors (Aviva, Concord) in the cross‑border scalability of a UK‑originated health‑tech platform. With 80 % of its workforce now U.S.-based, Scan.com is positioning itself as the de‑facto national diagnostic infrastructure layer, a role traditionally occupied by physical‑asset heavy operators such as RadNet.
Market Implications
By pairing growth equity with a sizable debt facility, Scan.com can pursue roll‑up strategies without immediate equity dilution, a play that could reshape the competitive landscape among digital health coordinators, AI‑triage specialists and traditional imaging operators. The company’s next steps—national network scaling, AI enhancements, and IPO preparation—will test whether an asset‑light, API‑driven approach can capture sufficient market share to challenge entrenched, capital‑intensive players.
Why It Matters
The infusion of $220 million gives Scan.com the runway to consolidate fragmented imaging centers across the United States, a move that could shift bargaining power toward the platform and away from traditional owners like RadNet. By leveraging non‑dilutive debt, Scan.com can acquire complementary scheduling and workflow tools without eroding existing shareholders, accelerating its path to a national, asset‑light infrastructure.
For competitors, the raise raises the stakes. AI‑centric triage firms such as Aidoc and Viz.ai must now consider integration or partnership strategies to stay relevant in a market where end‑to‑end scheduling, price transparency and rapid reporting are becoming baseline expectations. Traditional operators may feel pressure to either digitise their front‑end workflows or become acquisition targets for a platform that can instantly monetize idle scanner capacity.
The capital also underscores growing investor appetite for health‑tech platforms that blend SaaS scalability with tangible cost‑savings in high‑volume clinical services, potentially prompting further venture inflows into adjacent diagnostic‑coordination startups.
Key Points
- Scan.com raised $220 million, split into $90 million equity and $130 million debt
- Equity round led by Noteus Partners with Aviva Ventures, Concord Health Partners, YZR Capital and Oxford Capital participating
- Debt facility underwritten by VerisFi Capital and Atempo Growth for M&A and working‑capital
- Revenue run‑rate doubled to $165 million, serving over 900 000 patients
- Capital will fund U.S. network expansion, agentic AI deployment and a potential IPO
Analysis
Scan.com’s $220 million Series C blend of equity and debt underscores a broader trend: health‑tech platforms are increasingly using hybrid financing to scale SaaS infrastructure while preserving capital efficiency. The $90 million equity infusion, led by Noteus Partners, values the company at a multiple that, while undisclosed, likely reflects a premium on its $165 million run‑rate and high‑margin SaaS model. The $130 million debt facility, earmarked for roll‑up acquisitions, enables Scan.com to pursue a consolidation play without diluting existing shareholders, a strategy that could compress valuation multiples for later-stage health‑tech deals.
From an operator perspective, the capital supports rapid deployment of Scan.com’s agentic AI, which automates referral routing, eligibility checks and price negotiation—functions that traditionally required labor‑intensive back‑office teams. By reducing manual touchpoints, the platform can improve net revenue retention (NRR) and drive higher gross margins, aligning with investor expectations for scalable SaaS businesses.
The financing also signals confidence in the U.S. diagnostic imaging market’s shift toward API‑driven orchestration. As fragmented imaging centers become more networked, SaaS providers that can aggregate capacity and provide transparent pricing will command premium pricing power. For investors, Scan.com’s path to an IPO offers a potential exit at a valuation that reflects both SaaS multiples and the underlying $100 billion imaging market, setting a benchmark for future health‑tech IPOs.
Overall, the round illustrates how capital‑intensive health sectors can be transformed through SaaS economics, debt‑leveraged roll‑ups, and AI‑enabled workflow automation, a playbook that may be replicated across other fragmented clinical services.